We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WEN:NASDAQWendy's Company (The) Analysis

Data as of 2026-05-10 - not real-time

$7.30

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The stock is trading below its 50‑day and 200‑day moving averages, confirming a longer‑term bearish bias, while the 20‑day average sits just under the current price, hinting at a narrow short‑term cushion. The MACD histogram has turned positive, offering a modest bullish signal, and the RSI sits in the upper‑mid 50s, suggesting no immediate overbought pressure. Volume has been on the rise, supporting the recent price moves toward the identified resistance around $7.44, while a firm support near $6.37 remains intact.
Fundamental backdrop: Valuation appears attractive on a price‑to‑sales and price‑to‑earnings basis, yet the price‑to‑book multiple is steep relative to the modest book value. The company carries an extreme debt load, with debt far exceeding cash, which amplifies financial risk despite a solid free cash flow generation and a generous 8% dividend yield. Recent quarterly results showed a modest revenue uptick of 3.3% YoY but earnings per share slipped, and consensus expectations anticipate a further earnings decline. Analyst consensus is neutral (hold) amid “extreme greed” market sentiment, underscoring the tension between attractive yield and high leverage.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish longer‑term moving average alignment
  • Positive MACD crossover offering limited upside
  • High dividend yield offset by leverage concerns

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustained dividend income potential
  • Continued revenue volatility and earnings pressure
  • Elevated debt‑to‑equity ratio limiting financial flexibility

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Attractive valuation multiples relative to sales and earnings
  • Stable cash flow supporting dividend payments
  • Potential for balance‑sheet deleveraging and operational turnaround

Key Metrics & Analysis

Financial Health

Revenue Growth-5.50%
Profit Margin7.58%
P/E Ratio9.5
ROE87.64%
ROA4.24%
Debt/Equity3531.19
P/B Ratio11.8
Op. Cash Flow$344.5M
Free Cash Flow$171.2M

Technical Analysis

TrendBearish
RSI59.1
Support$6.37
Resistance$7.44
MA 20$6.89
MA 50$7.02
MA 200$8.44
MACDBullish
VolumeIncreasing
Fear & Greed Index90.73

Valuation

Target Price$7.72
Upside/Downside5.70%
GradeFair
TypeBlend
Dividend Yield8.03%

Risk Assessment

Beta0.52
Volatility38.50%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.